Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 37

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 37
---
 than 5% of our common stock;

• each named executive officer;

• each of our directors; and

• all executive officers and directors as a group.

Beneficial ownership is determined in accordance with the rules of the SEC and generally includes voting or investment power with respect to securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares beneficially owned, subject to community property laws where applicable. Common stock (i) subject to options that are currently exercisable or exercisable within 60 days of March 1, 2025 and (ii) underlying restricted stock units that are scheduled to vest within 60 days of March 1, 2025, are deemed to be outstanding and to be beneficially owned by the person holding any such options or restricted stock units for the purpose of computing the beneficial ownership of that person (including for the purpose of computing beneficial ownership of all current directors and officers), but are not treated as outstanding for the purpose of computing the beneficial ownership of any other person.

Percentages of beneficial ownership of our common stock in the table is based on 105,841,422 shares of common stock issued and outstanding on March 1, 2025.

| Name of Beneficial Owners                                            |     | Shares 
 Owned  |     |            |     | Shares                         
 That May Be Acquired Within 60 
 Days                           |     |           |     | Total        
 Shares       
 Beneficially 
 Owned        |     |            |     | Percentage 
 of         
 Beneficial 
 Ownership  |      |   |
| 5% Stockholders (other than directors and named executive officers): |     |        |     |            |     |                                |     |           |     |              |     |            |     |            |      |   |
| Gilead Sciences, Inc.(1)                                             |     |        |     | 31,424,760 |     |                                |     | 8,575,464 |     |              |     | 40,000,224 |     |            | 35.0 | % |
| BlackRock, Inc.(2)                                                   |     |        |     |  9,732,399 |     |                                |     |         — |     |              |     |  9,732,399 |     |            |  9.2 | % |
| The Vanguard Group, Inc.(3)                                          |     |